Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Carlo Gambacorti-Passerini"'
Autor:
Tim H. Brümmendorf, Kathleen Turnbull, Eric Leip, Ewa Matczak, Hanna Jean Khoury, Nathalie Bardy-Bouxin, Mark Shapiro, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim, Anna G. Turkina
Publikováno v:
American Journal of Hematology
Long‐term efficacy and safety of bosutinib (≥4 years follow‐up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated‐phase [AP, n = 79] chronic myelo
Autor:
Sarit Assouline, Dong-Wook Kim, Vikram Mathews, Jie Jin, Zhi Xiang Shen, Edo Vellenga, H. Jean Khoury, Ricardo Pasquini, Andrey Zaritskey, Hagop M. Kantarjian, Simon Durrant, Tim H. Brümmendorf, Jorge E. Cortes, Anna G. Turkina, Francisco Cervantes, Carlo Gambacorti-Passerini, Kathleen Turnbull, Eric Leip, Tamas Masszi, Virginia Kelly, Nadine Besson
Publikováno v:
American Journal of Hematology, 89(7), 732-742. Wiley
American Journal of Hematology
American Journal of Hematology
Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label stud
Autor:
Dong-Wook Kim, Irina Dyagil, Athena Countouriotis, Tim H. Brümmendorf, Hagop M. Kantarjian, Hemant Malhotra, Karin Gogat, Carlo Gambacorti-Passerini, Jorge E. Cortes, Christine Powell, Laimonas Griskevicius
Publikováno v:
Journal of Clinical Oncology. 30:3486-3492
Purpose Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid le
Autor:
Tim H. Brümmendorf, Angela Volkert, Steven Arkin, Junyuan Wang, Nadine Besson, H. Jean Khoury, Zhi Xiang Shen, Ricardo Pasquini, Richat Abbas, Dong-Wook Kim, Hagop M. Kantarjian, Jorge E. Cortes, Eric Leip, Carlo Gambacorti-Passerini, Anna G. Turkina
Publikováno v:
Blood. 118:4567-4576
Bosutinib, a dual Src/Abl kinase inhibitor, has shown potent activity against chronic myeloid leukemia (CML). In this phase 1/2 study we evaluated bosutinib in patients with chronic phase imatinib-resistant or imatinib-intolerant CML. Part 1 was a do
Autor:
Ilaria Elena Palamà, Ross Rinaldi, Roberto Cingolani, Nicola Di Renzo, Carlo Gambacorti-Passerini, Stefano Leporatti, Giuseppe Gigli, Addolorata Coluccia, Michele Maffia, Emanuela de Luca
Publikováno v:
Nanomedicine (London. Online) 5 (2010): 419–431. doi:10.2217/nnm.10.8
info:cnr-pdr/source/autori:Ilaria Elena Palamà, Stefano Leporatti, Emanuela De Luca, Carlo Gambacorti-Passerini, Nicola Di Renzo, Michele Maffia, Ross Rinaldi, Giuseppe Gigli, Roberto Cingolani, and Addolorata M.L. Coluccia./titolo:Imatinib-Loaded polyelectrolyte microcapsules for sustained targeting of BCRABL+ leukemia stem cells/doi:10.2217%2Fnnm.10.8/rivista:Nanomedicine (London. Online)/anno:2010/pagina_da:419/pagina_a:431/intervallo_pagine:419–431/volume:5
Nanomedicine (Lond., Print) (2010).
info:cnr-pdr/source/autori:Palamà I.E., Leporatti S., de Luca E., Di Renzo N., Maffia M., Gambacorti-Passerini C., Rinaldi R., Gigli G., Cingolani R. and Coluccia A.M.L./titolo:Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL(+) leukemia stem cells/doi:/rivista:Nanomedicine (Lond., Print)/anno:2010/pagina_da:/pagina_a:/intervallo_pagine:/volume
info:cnr-pdr/source/autori:Ilaria Elena Palamà, Stefano Leporatti, Emanuela De Luca, Carlo Gambacorti-Passerini, Nicola Di Renzo, Michele Maffia, Ross Rinaldi, Giuseppe Gigli, Roberto Cingolani, and Addolorata M.L. Coluccia./titolo:Imatinib-Loaded polyelectrolyte microcapsules for sustained targeting of BCRABL+ leukemia stem cells/doi:10.2217%2Fnnm.10.8/rivista:Nanomedicine (London. Online)/anno:2010/pagina_da:419/pagina_a:431/intervallo_pagine:419–431/volume:5
Nanomedicine (Lond., Print) (2010).
info:cnr-pdr/source/autori:Palamà I.E., Leporatti S., de Luca E., Di Renzo N., Maffia M., Gambacorti-Passerini C., Rinaldi R., Gigli G., Cingolani R. and Coluccia A.M.L./titolo:Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL(+) leukemia stem cells/doi:/rivista:Nanomedicine (Lond., Print)/anno:2010/pagina_da:/pagina_a:/intervallo_pagine:/volume
Aim: The lack of sensitivity of chronic myeloid leukemia (CML) stem cells to imatinib mesylate (IM) commonly leads to drug dose escalation or early disease relapses when therapy is stopped. Here, we report that packaging of IM into a biodegradable ca
Autor:
Elisa Sala, Alfonso Zambon, Stefania Brussolo, Luca Mologni, Vittorio Lucchini, Edoardo Marchesi, Loredana Cleris, Loris Moretti, Sara Redaelli, Arianna Donella-Deana, Franca Formelli, Carlo Gambacorti-Passerini, Peter Drueckes, Rosalind H. Gunby, Miriam Puttini, Michael H.G. Kubbutat, Leonardo Scapozza
Publikováno v:
Haematologica. 93:653-661
Background: Resistance to imatinib is an important clinical issue in the treatment of Philadelphia chromosomepositive leukemias which is being tackled by the development of new, more potent drugs, such as the dual Src/Abl tyrosine kinase inhibitors d
Autor:
Sabrina Crivellaro, Ubaldo Familiari, Mara Brancaccio, Emilia Turco, Alessandro Morotti, Giovanna Carrà, Emilia Giugliano, Rocco Piazza, Mauro Papotti, Juan Carlos Cutrin, Federica Fusella, Cristina Panuzzo, Emilio Hirsch, Carlo Gambacorti-Passerini, Giuseppe Saglio, Giovanna Rege-Cambrin, Lorenzo Silengo, Guido Tarone, Pier Paolo Pandolfi, Roberta Ferretti, Annalisa Camporeale, Irene Franco, Augusta Di Savino, Stefania Rocca, Barbara Miniscalco
We recently described morgana as an essential protein able to regulate centrosome du- plication and genomic stability, by inhibiting ROCK. Here we show that morgana 1/2 mice spontaneously develop a lethal myeloproliferative disease resembling human a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8691fd371733cfeef1e5e66b04c1e13a
http://hdl.handle.net/10281/95036
http://hdl.handle.net/10281/95036
Autor:
Karin Gogat, Tim H. Brümmendorf, Ladan Duvillie, Carmino Antonio De Souza, François Guilhot, Dmitri Pavlov, Athena Countouriotis, Jorge E. Cortes, Carlo Gambacorti-Passerini
Publikováno v:
British journal of haematology 168(1), 69-81 (2015). doi:10.1111/bjh.13108
British Journal of Haematology
British Journal of Haematology
British journal of haematology 168(1), 69-81 (2015). doi:10.1111/bjh.13108
Published by Wiley-Blackwell, Oxford [u.a.]
Published by Wiley-Blackwell, Oxford [u.a.]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5bc216ff8a7553ca77ca7ac7c0efb44
Autor:
Leonardo Scapozza, Sara Redaelli, Shaheen Ahmed, Rosalind H. Gunby, Carlo Gambacorti-Passerini, Luca Mologni, Marc Gasser, Valentina Belloni, Carmen J Tartari, Roberta Sottocornola
Publikováno v:
Journal of Medicinal Chemistry. 49:5759-5768
Anaplastic lymphoma kinase (ALK) is a valid target for anticancer therapy; however, potent ALK inhibitors suitable for clinical use are lacking. Because the majority of described kinase inhibitors bind in the ATP pocket of the kinase domain, we have
Autor:
Monica Fumagalli, Carlo Gambacorti-Passerini, Federica Colnaghi, Luisa Ponchio, Andrea Biondi, Lucia Tornaghi, Giovanni Giudici, Elena Maria Elli, Maria Dassi, Matteo Parma, Pietro Pioltelli, Paolo Perseghin, Enrico Pogliani
Publikováno v:
Transfusion. 45:1214-1220
BACKGROUND: Imatinib mesylate (IM) was introduced in chronic myeloid leukemia (CML) treatment in the late 1990s and substantially changed the therapeutic approach to the disease, by inducing complete cytogenetic response (CCR) in approximately 60 per